Seaside Therapeutics makes board appointments
This article was originally published in Scrip
Executive Summary
Seaside Therapeutics (US) has appointed Marc Beer, former CEO of ViaCell, Karen Dawes, president of Knowledge Decisions, and Dr Steven Paul, former executive vice-president for science and technology at Lilly, to its board of directors. They join Seaside's current board members – the company's president & CEO, Dr Randall Carpenter, and Peter Whipp, managing director of Barony Trust, Seaside's largest investor. Seaside is creating treatments to correct or improve the course of fragile X syndrome, autism and other neurodevelopmental disorders.